Novo Nordisk to acquire Inversago Pharma for up to $1.075 bn
The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.